Novel Btk Inhibitor Heads to Phase III Trials in Chronic Lymphocytic Leukemia

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
268 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Dec 11, 2011

An experimental oral drug given once a day is drawing responses from about 70% of patients with relapsed chronic lymphocytic leukemia. Dr. Susan O'Brien explains why investigators are excited about PCI-32765 in an interview at the annual meeting of the American Society of Hematology

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more